Lung cancer drug trial halted: new contender vs keytruda
NCT ID NCT06280196
First seen Jan 07, 2026 · Last updated Apr 25, 2026 · Updated 20 times
Summary
This study tested a new drug called BAT3306 against the standard treatment Keytruda, both given with chemotherapy, for people with stage IV non-squamous non-small cell lung cancer. The goal was to see if BAT3306 works as well and is as safe as Keytruda. The trial was terminated early, so results are limited. It included 162 adults who had not received prior treatment for their advanced cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.